SG11202103073SA - Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides - Google Patents
Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptidesInfo
- Publication number
- SG11202103073SA SG11202103073SA SG11202103073SA SG11202103073SA SG11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA SG 11202103073S A SG11202103073S A SG 11202103073SA
- Authority
- SG
- Singapore
- Prior art keywords
- deliverability
- tolerability
- efficacy
- compositions
- methods
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743243P | 2018-10-09 | 2018-10-09 | |
| PCT/US2019/055362 WO2020076925A1 (en) | 2018-10-09 | 2019-10-09 | Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103073SA true SG11202103073SA (en) | 2021-04-29 |
Family
ID=70164024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103073SA SG11202103073SA (en) | 2018-10-09 | 2019-10-09 | Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210346463A1 (en) |
| EP (1) | EP3863607A4 (en) |
| JP (2) | JP2022502472A (en) |
| KR (1) | KR20210055792A (en) |
| CN (2) | CN113164390A (en) |
| AU (1) | AU2019356916B2 (en) |
| BR (1) | BR112021006643A8 (en) |
| CA (1) | CA3115770C (en) |
| IL (1) | IL282199A (en) |
| MX (1) | MX2021003574A (en) |
| SG (1) | SG11202103073SA (en) |
| WO (1) | WO2020076925A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159314A1 (en) | 2021-01-20 | 2022-07-28 | The University Of Southern California | Use of naturally occurring cyclic peptides for treatment of sars-cov-2 infection |
| WO2023097211A1 (en) * | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022829A1 (en) * | 2001-03-30 | 2003-01-30 | Wendy Maury | Novel antiviral activities primate theta defensins and mammalian cathelicidins |
| US20060287221A1 (en) * | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
| CN113304250A (en) * | 2003-11-20 | 2021-08-27 | 诺和诺德股份有限公司 | Propylene glycol-containing peptide formulations optimized for production and use in injection devices |
| CN103732239A (en) * | 2011-06-02 | 2014-04-16 | 加利福尼亚大学董事会 | Blockade of inflammatory proteases with theta-defensins |
| JP6219277B2 (en) * | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | Oral treatment of inflammatory bowel disease |
| WO2016059593A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of protein drugs and process for its preparation |
| US20170035845A1 (en) * | 2015-08-07 | 2017-02-09 | The Regents Of The University Of California | Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression |
-
2019
- 2019-10-09 BR BR112021006643A patent/BR112021006643A8/en unknown
- 2019-10-09 CN CN201980081658.0A patent/CN113164390A/en active Pending
- 2019-10-09 KR KR1020217013534A patent/KR20210055792A/en active IP Right Grant
- 2019-10-09 EP EP19870455.3A patent/EP3863607A4/en active Pending
- 2019-10-09 US US17/283,384 patent/US20210346463A1/en active Pending
- 2019-10-09 AU AU2019356916A patent/AU2019356916B2/en active Active
- 2019-10-09 CA CA3115770A patent/CA3115770C/en active Active
- 2019-10-09 CN CN202311163732.8A patent/CN117379529A/en active Pending
- 2019-10-09 JP JP2021520316A patent/JP2022502472A/en active Pending
- 2019-10-09 MX MX2021003574A patent/MX2021003574A/en unknown
- 2019-10-09 WO PCT/US2019/055362 patent/WO2020076925A1/en active Application Filing
- 2019-10-09 SG SG11202103073SA patent/SG11202103073SA/en unknown
-
2021
- 2021-04-08 IL IL282199A patent/IL282199A/en unknown
-
2023
- 2023-08-03 JP JP2023127202A patent/JP2023133565A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022502472A (en) | 2022-01-11 |
| IL282199A (en) | 2021-05-31 |
| MX2021003574A (en) | 2021-08-27 |
| US20210346463A1 (en) | 2021-11-11 |
| EP3863607A4 (en) | 2022-07-06 |
| CN117379529A (en) | 2024-01-12 |
| BR112021006643A8 (en) | 2022-12-06 |
| CA3115770A1 (en) | 2020-04-16 |
| AU2019356916A1 (en) | 2021-05-06 |
| WO2020076925A1 (en) | 2020-04-16 |
| KR20210055792A (en) | 2021-05-17 |
| AU2019356916B2 (en) | 2022-12-01 |
| CN113164390A (en) | 2021-07-23 |
| CA3115770C (en) | 2023-11-14 |
| EP3863607A1 (en) | 2021-08-18 |
| JP2023133565A (en) | 2023-09-22 |
| BR112021006643A2 (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273948A (en) | Compositions and methods for selective protein degradation | |
| SG11202007363TA (en) | Methods and compositions for therapeutic protein delivery | |
| EP3675639A4 (en) | Methods and compositions for making bacteriocins and antimicrobial peptides | |
| IL276169A (en) | Peptide yy pharmaceutical formulations, compositions, and methods | |
| EP3268050A4 (en) | Pore-forming protein conjugate compositions and methods | |
| IL287082A (en) | Methods and compositions for targeted protein degradation | |
| IL265796A (en) | Compositions comprising pedf-derived short peptides and uses thereof | |
| EP3592841A4 (en) | Methods and compositions for treating cancers using antisense | |
| IL282199A (en) | Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides | |
| EP3688011A4 (en) | Peptide compositions and methods of use thereof | |
| EP3642219A4 (en) | Peptide compositions and related methods | |
| EP3576764A4 (en) | Kras peptide vaccine compositions and method of use | |
| EP3655440A4 (en) | Compositions and methods for targeting cd33-expressing cancers | |
| ZA201908603B (en) | Hair compositions for damage treatment | |
| EP3697422A4 (en) | Cell-penetrating peptides for antisense delivery | |
| EP3626241A4 (en) | N-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof | |
| IL265831A (en) | Compositions and methods for protein expression and delivery | |
| EP3377085A4 (en) | Peptides and methods of treating endometriosis using the same | |
| IL276888A (en) | Pharmaceutical composition comprising timolol | |
| EP3638270A4 (en) | Compositions and methods for enhancing hyperthermia therapy | |
| EP3781945A4 (en) | Compositions and methods for treating endometriosis | |
| EP3576799A4 (en) | Ophthalmic compositions for therapeutic and prophylactic uses | |
| AU2017313589B2 (en) | Conjugate of minoxidil and peptide | |
| EP3693001A4 (en) | Peptide composition for treating excitatory neurotoxicity related injuries | |
| EP3893894A4 (en) | Modified netrin-1 peptides and compositions for cardioprotection |